-
Need to catch up on your reading when it comes to teen sexuality issues? Stay current on adolescent health topics with the following reviews of six recently published papers:
-
How can clinicians reach at-risk teens? Take a look at the SPOT (Supporting Positive Opportunities with Teens), a one-stop, drop-in center in St. Louis aimed specifically at the 13- to 24-year age group.
-
Review the list of oral contraceptives (OCs) in your current formulary. While it might seem there are several options, research scientists are focusing on development of new pills to expand women's choices.
-
Endometriosis is a common gynecologic disorders; about 3%-10% of American reproductive-age women have endometriosis.1 Dysmenorrhea is the most common symptom reported by patients with endometriosis. What is your approach when it comes to treatment of such pain?
-
When the female condom first gained Food and Drug Administration (FDA) approval in 1993, women's health advocates hailed it as a form of female-controlled protection; however, use of the method has been underwhelming among American women since its introduction.
-
How can Hispanic men be reached with an HIV prevention message? It's time to spread the word. While Hispanics/Latinos comprise 15% of the U.S. population, they accounted for 17% of all new HIV infections occurring in the United States in 2006.
-
Think about the last five women who have entered your examination room. How many of them have had genital herpes simplex virus Type 2 (HSV-2) infection?
-
In this issue: FDA warning on topical anesthetics; antipsychotics increase sudden cardiac death; the step up vs step down debate; treating pain, fatigue, mood, and sleep in fibromyalgia; FDA Actions.
-
One of the most common and poignant questions an ovarian cancer patient asks upon learning of her diagnosis is, "How did I get this?
-
The Women's Iinternational Study of Long Duration Oestrogen after the Menopause (WISDOM) trial was a randomized, controlled trial in the United Kingdom, Australia, and New Zealand, of 3721 women aged 50-69 treated with either combined 0.625 mg conjugated estrogens and 2.5/5.0 mg medroxyprogesterone, or placebo. The original plan was to randomize 22,300 women to the study that would last 10 years.